Suven Life Sciences Approves INR 248 Crore Share Allotment, Board Re-appointment, and New Singapore Subsidiary

The Board of Directors of Suven Life Sciences Limited convened on July 8, 2026, approving a series of major strategic and capital decisions.

Equity Expansion via Warrant Conversion

Suven Life Sciences has approved the allotment of 1,85,70,133 equity shares. Each share has a face value of INR 1 and was issued at a premium price of INR 134 per share, following the conversion of an equivalent number of fully paid warrants.

The company confirmed receipt of 100% of the consideration amount, aggregating to a total of INR 2,48,83,97,822 from 17 non-promoter investors.

The three largest allocations among the non-promoter allottees went to Tejas Trivedi with 37,31,343 shares, Ketan Chhotalal Sheth with 20,00,000 shares, and ITI Holdings and Investment Private Limited with 18,65,670 shares. Other notable individual and corporate investors included Arun Nahar, Jagdish N Master, Nilesh Kishore Shah, Nimesh Arvind Doshi, Oracular Advisory Private Limited, Atman Investments Private Limited, and Zapfin Teknologies Private Limited.

This preferential allotment directly impacts the company's financial structure:

Pre-issue Subscribed and Paid-up Capital: 26,39,92,553 shares (valued at INR 26,39,92,553)

Post-issue Subscribed and Paid-up Capital: 28,25,62,686 shares (valued at INR 28,25,62,686)

Five-Year Extension for Independent Director

Acting on recommendations from the Nomination and Remuneration Committee, the board approved the re-appointment of Dr. Vajja Sambasiva Rao as a Non-Executive Independent Director. His second five-year term will run from January 21, 2027, to January 20, 2032, subject to shareholder approval at the upcoming Annual General Meeting.

Dr. Rao is a highly credentialed academician holding a Master of Science and a Ph.D. in Chemistry from BITS Pilani, with further alumni ties to the University of Bielefeld in Germany. His extensive experience in governance, project strategy, and financial management includes past leadership roles as the Vice Chancellor of SRM University-AP, President of NIIT University, and Acting Vice-Chancellor of BITS Pilani. He currently serves as an Advisor to the BITS Pilani Amaravati Campus and sits on the Expert Committee of APSCHE for screening private universities.

Global Footprint: New Subsidiary in Singapore

Looking to advance its clinical development capabilities, Suven Life Sciences announced the upcoming incorporation of a wholly-owned subsidiary in Singapore, to be named Suven Neurosciences Pte. Ltd.

The new entity will operate as a clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutics for neurological and other disorders.

Suven Life Sciences will maintain 100% control and ownership of the subsidiary. The initial cost of subscription is set at SGD 1.00 per share, with a total planned investment amount of USD 100.00 million. The initial paid-up capital will be fulfilled through a 100% cash consideration, to be deployed in one or more tranches based on upcoming business milestones.

Shares of Suven Life Sciences Limited was last trading in BSE at Rs. 358.20 as compared to the previous close of Rs. 346.20. The total number of shares traded during the day was 206780 in over 3335 trades.

The stock hit an intraday high of Rs. 370.70 and intraday low of 339.80. The net turnover during the day was Rs. 73468312.00.

Source : Equity Bulls

Keywords

SuvenLifeSciences INE495B01038 Pharmaceuticals SharesAllotment